Jens Wrammert 1 , 2 , Dimitrios Koutsonanos 2 , Gui-Mei Li 1 , 2 , Srilatha Edupuganti 4 , 5 , Jianhua Sui 6 , Michael Morrissey 8 , Megan McCausland 1 , 2 , Ioanna Skountzou 2 , Mady Hornig 9 , W. Ian Lipkin 9 , Aneesh Mehta 3 , Behzad Razavi 5 , Carlos Del Rio 3 , 4 , 10 , Nai-Ying Zheng 8 , Jane-Hwei Lee 8 , Min Huang 8 , Zahida Ali 8 , Kaval Kaur 8 , Sarah Andrews 8 , Rama Rao Amara 1 , 2 , Youliang Wang 1 , Suman Ranjan Das 11 , Christopher David O'Donnell 12 , Jon W. Yewdell 11 , Kanta Subbarao 12 , Wayne A. Marasco 6 , Mark J. Mulligan 4 , Richard Compans 1 , Rafi Ahmed , 1 , 2 , Patrick C. Wilson , 8
17 January 2011
Although scarce after annual influenza vaccination, B cells producing antibodies capable of neutralizing multiple influenza strains are abundant in humans infected with pandemic 2009 H1N1 influenza.
The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic H1N1 infection were broadly cross-reactive against epitopes in the hemagglutinin (HA) stalk and head domain of multiple influenza strains. The antibodies were from cells that had undergone extensive affinity maturation. Based on these observations, we postulate that the plasmablasts producing these broadly neutralizing antibodies were predominantly derived from activated memory B cells specific for epitopes conserved in several influenza strains. Consequently, most neutralizing antibodies were broadly reactive against divergent H1N1 and H5N1 influenza strains. This suggests that a pan-influenza vaccine may be possible, given the right immunogen. Antibodies generated potently protected and rescued mice from lethal challenge with pandemic H1N1 or antigenically distinct influenza strains, making them excellent therapeutic candidates.